MYGN
MYGN clinical trials: MYRIAD GENETICS INC
Every trial on ClinicalTrials.gov where MYRIAD GENETICS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 18
- Trials linked
- 0
- As lead sponsor
- 18
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
MYGN on the catalyst calendar · MYGN registry changes
- Primary completion Jun 2027Sponsor estimateNo phase registeredNCT07052266Trial of Combined Obstetric Carrier Screening and Hereditary Cancer ScreeningWeill Medical College of Cornell University · Hereditary Cancer SyndromesRecruitingMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2025ActualNo phase registeredNCT04245176Genetic Testing for All Breast Cancer Patients (GET FACTS)Brigham and Women's Hospital · Breast CancerCompletedMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 22, 2024ActualPhase 4NCT05457257Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer...AstraZeneca · Metastatic Castration-resistant Prostate CancerActive, not recruitingAZNLeadMYGNCollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 17, 2019ActualPhase 3NCT02655016A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line...Tesaro, Inc. · Ovarian NeoplasmsActive, not recruitingGSKLeadMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 1NCT04150042SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem CellsGeneral Oncology, Inc. · Pancreatic Adenocarcinoma MetastaticRecruitingMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2027Sponsor estimatePhase 2NCT05642780SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid TumorsKlus Pharma Inc. · Solid TumorActive, not recruitingMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2019ActualPhase 2NCT01982448Cisplatin vs Paclitaxel for Triple Negative Breast CancerDana-Farber Cancer Institute · Triple Negative Breast CancerCompletedMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 15, 2019ActualNo phase registeredNCT03076242Genetic Evaluation of Men (GEM)Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Prostate CancerTerminatedMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 4, 2023ActualPhase 1NCT03150810Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With...BeiGene · Locally Advanced or Metastatic Solid TumorsCompletedONCLeadMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2, 2020ActualPhase 3NCT03402841Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer PatientsAstraZeneca · Non-Germline BRCA Mutated Ovarian Cancer
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 4, 2019ActualPhase 3NCT02987543Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer...AstraZeneca · Metastatic Castration-resistant Prostate Cancer
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2017ActualNo phase registeredNCT02773004Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive...UNICANCER · Breast CancerCompletedMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2017ActualPhase 3NCT01968213Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)pharmaand GmbH · Ovarian CancerCompletedMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 5, 2019ActualPhase 2NCT01891344A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal...pharmaand GmbH · Ovarian CancerCompletedMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 22, 2016ActualPhase 3NCT01847274A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerTesaro, Inc. · Ovarian NeoplasmsCompletedGSKLeadMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2018ActualPhase 1/Phase 2NCT02354131Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian CancerNordic Society of Gynaecological Oncology - Clinical Trials Unit · Ovarian CancerCompletedMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2018ActualPhase 2NCT02354586A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensTesaro, Inc. · Ovarian NeoplasmsCompletedGSKLeadMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2017ActualNo phase registeredNCT03081455Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer SyndromesMyriad Genetic Laboratories, Inc. · Hereditary CancerCompletedMYGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 18 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner